Mangalam Drugs Q2 FY27 Unaudited Results: Net Loss Widens, Faces Going Concern Uncertainty
Mangalam Drugs reported unaudited Q2 FY27 results with a net loss of ₹720.93 lakhs (standalone) and ₹5.66 lakhs (consolidated). The company faces going concern uncertainty due to NPA classification with banks and excess current liabilities over assets. Discussions with lenders are ongoing.
The announcement details significant financial distress, including NPA classification and a going concern uncertainty, which has a material impact on the company's financial health and investor confidence.
The company reported a net loss for the quarter and half-year, and faces significant going concern uncertainties due to banking issues and a weak current asset position. This indicates a negative financial outlook.
Mangalam Drugs and Organics Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a net loss for the period. A significant concern highlighted in the limited review report is the classification of cash credit accounts with two consortium banks as Non-Performing Assets (NPAs) since October 2025, leading to a demand notice from Bank of Baroda for ₹2,671.57 lakhs. Furthermore, current liabilities exceeded current assets by ₹4,521.21 lakhs as of September 30, 2026. These conditions indicate a material uncertainty regarding the company's ability to continue as a going concern. Despite these challenges, the Board considers it appropriate to prepare the financial results on a going concern basis, citing the company's net worth, continuing operations, and ongoing discussions with lenders to resolve the debt.
The Board of Directors met on November 5, 2026, to approve these un-audited financial results (standalone and consolidated) along with the limited review report. The company's business activity falls within a single reportable segment: 'Manufacturing of Bulk Drugs'.
In standalone results for the quarter ended September 30, 2026, the company reported a net loss of ₹720.93 lakhs. For the half-year ended September 30, 2026, the standalone net loss stood at ₹1,476.29 lakhs. Consolidated results for the quarter ended September 30, 2026, showed a net loss of ₹5.66 lakhs, while the half-year ended September 30, 2026, reported a consolidated net loss of ₹15,455 lakhs. The company also noted that the scheme of Merger by Absorption of Mangalam Laboratories Private Limited and Shri J& Pharma Private Limited with Mangalam Drugs and Organics Limited is yet to be heard by the National Company Law Tribunal.
What to do with a filing like this
Mangalam Drugs And Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mangalam Drugs And Organics Limited. Read the original for the full detail.